CNR2 and melanoma: Activation of CB receptors by the mixed CB1 and CB2 agonist—WIN 55,212-2 can significantly block the formation of new blood vessels, decrease proliferation, tumor growth and induce apoptosis of melanoma cells in the mouse exografted tumor model (Table 1).